Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Flavio G. Rocha

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6257-5796; OpenAlex author ID A5034255041. Sources: OpenAlex.

Their work

Papers
20 (first author 5, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 4 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers

Papers 20

  1. Rapid metastatic recurrence after pancreatic cancer resection: a multi-center, regional analysis of trends in surgical failure over two decades. Co-author DOI 10.1016/j.hpb.2024.08.006↗
  2. Reply to: Letter to Editor Entitled "Endoscopy's Evolving Role in Locally Advanced and Borderline Resectable Pancreatic Cancer". First author DOI 10.1245/s10434-024-15859-9↗
  3. Socioeconomic and Geographic Disparities in the Referral and Treatment of Pancreatic Cancer at High-Volume Centers. Co-author DOI 10.1001/jamasurg.2022.6709↗
  4. Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09367-9↗
  5. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1136/esmoopen-2019-000668↗
  6. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Co-author DOI 10.1634/theoncologist.2019-0878↗
  7. Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. Last author DOI 10.1002/jso.25498↗
  8. Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/jcm8081205↗
  9. Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged? Last author DOI 10.1002/jso.25060↗
  10. Modified Appleby procedure for locally advanced pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2018.01.004↗
  11. Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma? Last author DOI 10.1016/j.hpb.2018.03.014↗
  12. Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival? Last author DOI 10.1245/s10434-018-6334-8↗
  13. Surgical strategies and novel therapies for locally advanced pancreatic cancer. First author DOI 10.1002/jso.24654↗
  14. Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience. Co-author DOI 10.1016/j.amjsurg.2016.04.008↗
  15. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Co-author DOI 10.1245/s10434-016-5716-z↗
  16. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1067/j.cpsurg.2015.07.003↗
  17. Posterior 'superior mesenteric artery first' approach for resection of locally advanced pancreatic cancer. First author DOI 10.1245/s10434-013-3431-6↗
  18. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. First author DOI 10.1245/s10434-014-3486-z↗
  19. Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? Co-author DOI 10.1007/s11605-012-2071-7↗
  20. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. Co-author DOI 10.1371/journal.pone.0040157↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adnan A. Alseidi · 11 shared papers, 2014–2020 · strength 0.84
  2. Ranish K. Patel · 2 shared papers, 2024 · strength 0.66
  3. Vincent J. Picozzi · 8 shared papers, 2014–2020 · strength 0.61
  4. Brett C. Sheppard · 2 shared papers, 2023–2024 · strength 0.39
  5. Thomas Lee Sutton · 2 shared papers, 2023–2024 · strength 0.39
  6. William Scott Helton · 5 shared papers, 2015–2020 · strength 0.39
  7. Richard A. Kozarek MD · 5 shared papers, 2017–2019 · strength 0.38
  8. Scott W. Helton · 5 shared papers, 2014–2019 · strength 0.35
  9. John Bart Rose · 4 shared papers, 2014–2020 · strength 0.32
  10. Pavlos Papavasiliou · 1 shared paper, 2024 · strength 0.21
  11. Patrick Joseph Worth · 1 shared paper, 2024 · strength 0.21
  12. Stephen Y. Oh · 3 shared papers, 2017–2018 · strength 0.20
  13. Morgan Bonds · 1 shared paper, 2019 · strength 0.20
  14. Aaron J. Grossberg · 1 shared paper, 2023 · strength 0.18
  15. Skye C. Mayo · 1 shared paper, 2023 · strength 0.18
  16. Charles D. Lopez · 1 shared paper, 2023 · strength 0.18
  17. Jad Abou‐Khalil · 1 shared paper, 2017 · strength 0.15
  18. Shanley B. Deal · 1 shared paper, 2018 · strength 0.14
  19. Jordan Michael Winter · 2 shared papers, 2012–2020 · strength 0.13
  20. Jong Jin Hyun · 1 shared paper, 2019 · strength 0.10
  21. Ewa Carrier · 1 shared paper, 2020 · strength 0.10
  22. Kabir Mody · 1 shared paper, 2020 · strength 0.10
  23. Michael Jon Pishvaian · 1 shared paper, 2020 · strength 0.10
  24. Kimberly A. Bertens · 1 shared paper, 2018 · strength 0.08
  25. Farzad Alemi · 1 shared paper, 2015 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.